No connection

Search Results

EVO

BEARISH
$2.69 Live
Evotec SE · NASDAQ
Target $5.29 (+96.8%)
$2.31 52W Range $4.8

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 09, 2026
Market cap
$963.68M
P/E
N/A
ROE
-18.0%
Profit margin
-21.0%
Debt/Equity
0.61
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
60%
EVO shows bearish fundamentals based on deterministic rules. Financial strength is strong (F-Score 6/9). Concerns include weak profitability or high valuation.

Key Strengths

Company has established market presence

Key Risks

Low profit margin of -21.0%
Declining revenue (-11.4%)
Weak ROE of -18.0%

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
33
Weak
Value
50
Future
35
Past
30
Health
50
Dividend
0
AI Verdict
EVO shows bearish fundamentals based on deterministic rules. Financial strength is strong (F-Score 6/9). Concerns include weak profitability or high valuation.
Key drivers: Company has established market presence, Low profit margin of -21.0%, Declining revenue (-11.4%)
Confidence
20%
Value
50/100

Rule-based valuation (P/E + Graham).

Positives
  • Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Future
35/100

Rule-based growth outlook.

Positives
  • Insufficient data for clear positives.
Watchpoints
  • Revenue is contracting.
Past
30/100

Historical performance + price trend: Shares moved -85.8% over 5Y and -11.5% over 1Y.

Positives
  • Insufficient data for clear positives.
Watchpoints
  • ROE only -18.0%.
  • Thin profit margins.
Health
50/100

Balance sheet & liquidity (Z-Score: N/A).

Positives
  • Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Dividend
0/100

Dividend policy fallback.

Positives
  • Insufficient data for clear positives.
Watchpoints
  • No regular dividend payments.

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$2.69
Analyst Target
$5.29
Upside/Downside
+96.8%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for EVO and closest competitors.

Updated 2026-04-08
EVO
Evotec SE
Primary
5Y
-85.8%
3Y
-75.5%
1Y
-11.5%
6M
-32.4%
1M
-11.2%
1W
+5.9%
CLO
Clover Health Investments, Corp.
Peer
5Y
-78.5%
3Y
+126.7%
1Y
-40.8%
6M
-29.6%
1M
-5.0%
1W
+8.0%
AST
Astrana Health, Inc.
Peer
5Y
-19.7%
3Y
-41.8%
1Y
-41.4%
6M
-36.4%
1M
-7.6%
1W
+2.4%
AKT
Aktis Oncology, Inc.
Peer
5Y
-15.2%
3Y
-15.2%
1Y
-15.2%
6M
-15.2%
1M
+5.2%
1W
+1.0%
ABU
Arbutus Biopharma Corporation
Peer
5Y
+34.8%
3Y
+48.0%
1Y
+34.4%
6M
+0.9%
1M
+3.2%
1W
+6.6%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-14.16
PEG Ratio
N/A
P/B Ratio
1.03
P/S Ratio
1.27
EV/Revenue
0.96
EV/EBITDA
55790.9
Market Cap
$963.68M

Profitability

Profit margins and return metrics

Profit Margin -21.02%
Operating Margin -26.6%
Gross Margin 10.82%
ROE -17.98%
ROA -2.69%

Growth

Revenue and earnings growth rates

Revenue Growth -11.4%
Earnings Growth N/A
Q/Q Revenue Growth -11.36%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.61
Moderate
Current Ratio
2.12
Strong
Quick Ratio
1.15
Good
Cash/Share
$1.33

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q3 2025

Revenue
$0.2B
Gross Margin
-0.0%
Op. Margin
-27.2%
Net Margin
-26.3%
Total Assets
$1.8B
Liabilities
$1.0B
Equity
$0.8B
Debt/Equity
1.22x
Operating CF
$-0.1B
CapEx
$-0.0B
Free Cash Flow
$-0.1B
FCF Yield
132%

Quarterly Earnings History

EPS performance vs analyst estimates

2025-11-05
$-0.12
+28.0% surprise
2025-08-13
$-0.12
+7.7% surprise
2025-05-06
$-0.09
+25.0% surprise
2025-04-17
$-0.11

Healthcare Sector Comparison

Comparing EVO against 189 companies in the Healthcare sector (17 bullish, 63 neutral, 109 bearish)
Return on Equity (ROE)
-17.98%
This Stock
vs
-44.08%
Sector Avg
-59.2% (Below Avg)
Profit Margin
-21.02%
This Stock
vs
-19.57%
Sector Avg
+7.4% (Better)
Debt to Equity
0.61
This Stock
vs
5.1
Sector Avg
-88.1% (Less Debt)
Revenue Growth
-11.4%
This Stock
vs
108.17%
Sector Avg
-110.5% (Slower)
Current Ratio
2.12
This Stock
vs
3.39
Sector Avg
-37.5% (Weaker)

Similar Companies

Peer comparison within the same industry

Past News Coverage

Recent headlines mentioning EVO from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile